20
Participants
Start Date
February 1, 2023
Primary Completion Date
January 1, 2026
Study Completion Date
February 1, 2026
Semaglutide Injectable Product (not provided by the study)
"Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall."
RECRUITING
UCLA Health, Los Angeles
University of California, Los Angeles
OTHER